Please assess the completion status of the following clinical trial:

Trial Title: VRC 605: Safety and Pharmacokinetics of a Human Monoclonal Antibody, VRC-HIVMAB075-00-AB (VRC07-523LS), Administered Intravenously or Subcutaneously to Healthy Adults

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 7.0

Eligibility Criteria:
* INCLUSION CRITERIA:~A volunteer must meet all of the following criteria:~* Able and willing to complete the informed consent process.~* 18 to 50 years of age.~* Based on history and examination, must be in good general health and without history of any of the conditions listed in the exclusion criteria.~* Willing to have blood samples collected, stored indefinitely, and used for research purposes.~* Able to provide proof of identity to the satisfaction of the study clinician completing the enrollment process.~* Willing to adhere to reduced risk sexual behavior during study participation.~* Screening laboratory values within 84 days prior to enrollment must meet the following criteria:~  * White Blood Cell (WBC) 2,500-12,000/mm\^3.~ * WBC differential either within institutional normal range or accompanied by the Principal Investigator (PI) or designee approval.~ * Platelets = 125,000 - 400,000/mm\^3.~ * Hemoglobin within institutional normal range.~ * Creatinine less than or equal to 1.1 x upper limit of normal (ULN).~ * Alanine aminotransferase (ALT) less than or equal to 1.25 x ULN.~* Negative for HIV infection by the FDA approved method of detection.~* Female-Specific Criteria:~  * If a woman is of reproductive potential and sexually active with a male partner, then she agrees to use an effective means of birth control from the time of study enrollment until the last study visit, or to be monogamous with a partner who has had a vasectomy.~ * Negative Beta-HCG (human chorionic gonadotropin) pregnancy test (urine or serum) on day of enrollment for women presumed to be of reproductive potential.~EXCLUSION CRITERIA:~A volunteer will be excluded if one or more of the following conditions apply:~* Previous receipt of licensed or investigational monoclonal antibody.~* Weight \>115 kg.~* Any history of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis prior to enrollment that has a reasonable risk of recurrence during the study.~* Hypertension that is not well controlled.~* Woman who is breast-feeding, or planning to become pregnant during the study participation.~* Receipt of any investigational study agent within 28 days prior to enrollment.~* Any other chronic or clinically significant medical condition that in the opinion of the investigator would jeopardize the safety or rights of the volunteer, including but not limited to: diabetes mellitus type I, chronic hepatitis; OR clinically significant forms of: drug or alcohol abuse, asthma, autoimmune disease, psychiatric disorders, heart disease, or cancer.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: 1 mg/kg IV Single Dose (Type: EXPERIMENTAL): Group 1 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 1 mg/kg.
- Group 2: 5 mg/kg IV Single Dose (Type: EXPERIMENTAL): Group 2 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 5 mg/kg.
- Group 3: 5 mg/kg SC Single Dose (Type: EXPERIMENTAL): Group 3 subjects received a single SC injection of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 5 mg/kg.
- Group 4: 20 mg/kg IV Single Dose (Type: EXPERIMENTAL): Group 4 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 20 mg/kg.
- Group 5: 40 mg/kg IV Single Dose (Type: EXPERIMENTAL): Group 5 subjects received a single IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0 at a dose of 40 mg/kg.
- Group 6: 5 mg/kg SC Multiple Doses (Type: EXPERIMENTAL): Group 6 subjects received a SC injection of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0, Week 12 and Week 24 at a dose of 5 mg/kg.
- Group 7: 20 mg/kg IV Multiple Doses (Type: EXPERIMENTAL): Group 7 subjects received an IV infusion of VRC07-523LS (VRC-HIVMAB075-00-AB) on Day 0, Week 12 and Week 24 at a dose of 20 mg/kg.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete